Related Experiment Video
Updated: May 8, 2026
06:32
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone
Olga Zolochevska1, Jayne Ellis, Sangram Parelkar
11 Department of Pharmacology and Toxicology, The University of Texas Medical Branch , Galveston, TX 77555.
Human Gene Therapy
|September 14, 2013
Summary
Interleukin-27 (IL-27) gene therapy effectively reduced prostate cancer growth in bone metastases. This novel approach also helped normalize bone structure and boosted anti-tumor immune cells.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Prostate cancer frequently metastasizes to bone, creating a detrimental cycle involving tumor cells, osteoblasts, and osteoclasts, leading to bone lesions and pain.
- Interleukin-27 (IL-27), a novel cytokine, shows potential in inhibiting tumor growth and promoting regression in various cancer models, including prostate cancer.
Purpose of the Study:
- To investigate the therapeutic potential of IL-27 gene delivery in treating prostate cancer bone metastases.
- To evaluate the effects of IL-27 on prostate cancer cells, osteoblasts, and osteoclasts in vitro and in vivo.
Main Methods:
- Utilized sonoporation (sonodelivery) for in vivo IL-27 gene delivery to prostate cancer bone metastases in an immune-competent model.
- Assessed tumor growth reduction, gene expression changes, and effector cellular profiles post-treatment.
Main Results:
- IL-27 gene delivery significantly reduced prostate tumor growth at bone metastatic sites.
- Treatment with IL-27 promoted normalization of bone structure and enhanced the accumulation of effector immune cells within prostate tumors.
- Demonstrated the efficacy of sonodelivery as a method for IL-27 gene therapy in this model.
Conclusions:
- IL-27 holds promise as a dual-action therapeutic agent, targeting both prostate tumors and bone pathology in metastatic disease.
- Sonodelivery offers a simple and effective method for delivering IL-27-based gene therapy for prostate cancer bone metastases.
